Alnylam Pharmaceuticals (ALNY) Long-Term Debt Issuances (2021 - 2025)
Alnylam Pharmaceuticals' (ALNY) quarterly Long-Term Debt Issuances came in at -$680000.0 in Q4 2025, up 12.48% on a QoQ basis from -$777000.0 in Q4 2022.
Alnylam Pharmaceuticals (ALNY) Long-Term Debt Issuances (2021 - 2025) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 4 years of Long-Term Debt Issuances data on file, last reported at -$680000.0 in Q4 2025.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$680000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.5 million (down 100.14% YoY) and the FY2025 annual result came in at $645.7 million, changed N/A from the prior year.
- Long-Term Debt Issuances advanced to -$680000.0 in Q4 2025, from -$777000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $1.0 billion in Q3 2022 to a low of -$250.0 million in Q3 2021.
- A 3-year average of $191.4 million and a median of -$728500.0 in 2022 frame the typical range for Long-Term Debt Issuances.
- The widest YoY moves for Long-Term Debt Issuances: up 506.76% in 2022, down 506.76% in 2022.
- Tracing ALNY's Long-Term Debt Issuances over 3 years: stood at -$250.0 million in 2021, then surged by 99.69% to -$777000.0 in 2022, then climbed by 12.48% to -$680000.0 in 2025.
- The last three Long-Term Debt Issuances figures came in at -$680000.0 (Q4 2025), -$777000.0 (Q4 2022), and $1.0 billion (Q3 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -680,000.00 |
| Dec 31, 2025 | -680,000.00 |
| Dec 31, 2022 | 254.00 Mn |
| Dec 31, 2022 | 254.00 Mn |
| Sep 30, 2022 | 762.11 Mn |
| Sep 30, 2022 | 762.11 Mn |
| Sep 30, 2021 | -250.00 Mn |
| Sep 30, 2021 | -250.00 Mn |